Leishmaniasis, Cutaneous
An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.
Subtype terms (2)
More specific conditions that are subtypes of Leishmaniasis, Cutaneous in the MeSH hierarchy.
- Leishmaniasis, Diffuse Cutaneous
- Leishmaniasis, Mucocutaneous
7 drugs (4 approved, 3 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (3)
Phase 3 trials (15)
Phase 2 trials (14)
Phase 1 trials (6)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (38)
- Institut Pasteur
- Fundacion Nacional de Dermatologia
- Waisenmedizin e. V. Promoting Access to Essential Medicine
- Fundación Cardiovascular de Colombia
- United States Army
- World Health Organization
- Paulo Roberto Lima Machado
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Federal University of Bahia
- Federal University of Mato Grosso do Sul
- Kerman University of Medical Sciences
- Mashhad University of Medical Sciences
- Rio de Janeiro State University
- Universidad de Antioquia
- Universidad de Santander
- Universidad Industrial de Santander
- Cayetano Heredia University
- University of Tehran
- University of Freiburg
- Drugs for Neglected Diseases Initiative
- Isfahan University
- University of Bahia
- Instituto Conmemorativo Gorgas de Estudios de la Salud
- Instituto de Medicina Integral Professor Fernando Figueira
- Instituto Nacional de Infectologia, Brazil
- University of Erlangen-Nuremberg
- University of Akron
- Cardiovascular Foundation of Colombia
- Akron University
- The Alfred Berman Foundation for Medical Research
- +8 more
Organization Involved with Phase 2 Indications (24)
- AEterna Zentaris
- Immune Design
- Infan Industria Quimica Farmaceutica Nacional
- Centro de Investigaciones Bioclínicas de la Fundación Fader
- Foundation Fader
- Infectious Disease Research Institute
- National Institute of Allergy and Infectious Diseases (NIAID)
- Uniformed Services University of the Health Sciences
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
- Harvard University
- University of Heidelberg
- University of Khartoum
- University of York
- Fast Track Drugs and Biologics LLC
- Universidad Mayor San Simón, Cochabamba, Bolivia.
- Cenetrop
- AB Foundation for Medical Research
- University of Paris
- Ben Gurion University
- Bill and Melinda Gates Foundation
- German Federal Ministry of Education and Research
- Proyecto OSCAR
- Government of Spain
- Pontifical Catholic University of Rio Grande do Sul
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (2)